雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Current status and future prospects of clinical development of cancer immunotherapy Shigehisa Kitano 1 1Department of Experimental Therapeutics National Cancer Center Hospital Keyword: がん免疫療法 , 免疫チェックポイント阻害薬 , CTLA-4 , PD-1 , PD-L1 pp.1307-1316
Published Date 2019/10/10
DOI https://doi.org/10.18888/rp.0000001024
  • Abstract
  • Look Inside
  • Reference

Recent progress in cancer immunotherapy has been remarkable, especially the clinical development of immune checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies. These monoclonal antibodies(mAb)are directed to immune checkpoint molecules, which are expressed on immune cells and mediate signals to attenuate excessive immune reactions. Main mode of action of immune checkpoint inhibitors is to restore and augment the antitumor immune activities of cytotoxic T cells by blocking immune checkpoint molecules on T cells or their ligands on antigen presenting and tumor cells, etc. Based on preclinical data, some clinical trials have demonstrated the acceptable safety profiles and efficacies of immune checkpoint inhibitors in a variety of cancers. Several clinical trials have since investigated new agents, alone and in combination, for various cancers. In this review, the current development status of and future challenges in utilizing immune checkpoint inhibitors are introduced.


Copyright © 2019, KANEHARA SHUPPAN Co.LTD. All rights reserved.

基本情報

電子版ISSN 印刷版ISSN 0009-9252 金原出版

関連文献

もっと見る

文献を共有